---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018436"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:34:05.409539+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intellia reports Q4 net loss $132.2M; cash $1.0B; on track for Phase 3 NTLA-2001 in Q1 2024

## Summary
- Q4 2023 net loss $132.2M vs $113.4M YoY; R&D expenses rose $9.0M to $109.0M.
- Cash, equivalents and securities $1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
- On track to dose first patient in Phase 3 MAGNITUDE trial (NTLA-2001) for ATTR cardiomyopathy in Q1 2024.
- Plan to initiate Phase 3 of NTLA-2002 for hereditary angioedema in 2H24; positive interim Phase 1 data published in NEJM.
- Expanding pipeline: Phase 1 for NTLA-3001 (AATD) expected in 2024; collaboration with ReCode for cystic fibrosis.

## SEC filing metadata
- accession: 0000950170-24-018436
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/0000950170-24-018436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/ntla-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018436
- JSON: https://secwatch.observer/filing/0000950170-24-018436.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018436.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/0000950170-24-018436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.